Evidence map›Paper›PMID 39135958›Full record

ArticlePathogens & immunity2024

Diagnostic Utility of Pre-Genomic Hepatitis B RNA in the Evaluation of HBV/HIV Coinfection.

Kenneth E Sherman, Susan D Rouster, Heidi Meeds, Marion G Peters, Jason T Blackard, Paul S Horn, Timothy Archampong, Awewura Kwara, Mark Anderson, Michael Stec and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens & immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kenneth E ShermanDivision of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH.
Susan D RousterDivision of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH.
Heidi MeedsDivision of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH.
Marion G PetersDepartment of Medicine, Northwestern University, Chicago, IL.
Jason T BlackardDivision of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH.
Paul S HornDepartment of Pediatrics, University of Cincinnati; Neurology Division, Cincinnati Children's Medical Center, Cincinnati, OH.
Timothy ArchampongDepartment of Medicine and Therapeutics, University of Ghana Medical School, Accra, Ghana.
Awewura KwaraUniversity of Florida College of Medicine, Gainesville, FL.
Mark AndersonAbbott Laboratories, Abbott Diagnostics Division, Abbott Park, IL.
Michael StecAbbott Laboratories, Abbott Diagnostics Division, Abbott Park, IL.
Gavin A ClohertyAbbott Laboratories, Abbott Diagnostics Division, Abbott Park, IL.

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Biomarkers of Replication and Injury in HBV/HIVR21AI165171 · NIAID · UNIVERSITY OF CINCINNATI · PI SHERMAN, KENNETH E · 2021 to 2022
$444k
NIAID NIH HHS R21 AI165171NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701
6 · The paper itself

Abstract

Background: Newer biomarkers of Hepatitis B virus (HBV) infection and treatment response have not been well-characterized in individuals with HBV/HIV coinfection. Methods: Pre-genomic RNA (pgRNA) and quantitative HBsAg (qHBsAg) were used to evaluate the associations with baseline characteristics. Participants included two separate groups - 236 with HBV/HIV coinfection enrolled in a cross-sectional cohort in Ghana and 47 from an HBV nucleoside/nucleotide treatment trial comparing tenofovir to adefovir in the United States. Results: In both cohorts, HBe antigenemia was highly associated with pgRNA and HBV DNA levels. In the treatment cohort, pre-treatment pgRNA serum concentration was 7.0 log Conclusion: pgRNA and qHBsAg represent newer biomarkers of HBV replication that may help monitor response and treatment outcomes. HBV pgRNA is highly associated with both HBeAg and ALT and may predict both active replication from the closed circular DNA (cccDNA) template as well as hepatic injury.

Indexed as

HBVHBV DNAHIVpgRNAquantitative HBsAgtreatment

Identifiers

PMID39135958
PMCPMC11318280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.